beta blockers and glp-1 Bridging the gap between GLP1-receptor agonists cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology GLP-1 | Summary

Eli Lilly CEO David Ricks announces details of the Medicare GLP-1 bridge program, offering weight loss medications like Fondeo and Zepbound for $50 per month to 20 million eligible Medicare Part D patients starting July 1.

The wild card-to-uncertainty about GLP-1 meds growth will be reimbursement: spending will continue to accelerate with upside if more widely reimbursed, IQVIA projects

Tom White offers an example options trade for Eli Lilly.

Here we investigate the effects of liraglutide, a GLP-1 receptor agonist, in two well characterised transgenic mouse models of ALS (SOD1G93A and TDP-43Q331K) to determine if liraglutide could be a potential treatment in ALS patients

Lue asiantuntijan selke opas.

This state-of-the-art narrative review synthesizes current evidence from clinical trials, pharmacovigilance databases, and real-world cohorts to provide a comprehensive evaluation of the safety and tolerability of GLP-1RAs and tirzepatide